Nano-In
Introducing Nano-in™
The Future of Nucleic Acid Drug Delivery
What is Nano-in™ Drug Delivery?
Nano-in™ is a groundbreaking, proprietary biocompatible polymer developed by Speratum Biopharma. It combines two existing polymers—Polyethylenimine (PEI) and Polylactic-co-glycolic acid (PLGA)—to create a revolutionary platform for delivering nucleic acid-based drugs. This innovative approach addresses the limitations of traditional delivery systems in cancer therapies.
Key Features:
- Broad Applicability: Versatile nucleic acid delivery platform (RNA and DNA) for a wide range of therapeutic applications.
- In Vivo Delivery: Facilitates intravenous administration of any nucleic acid, regardless of size
- Targeted Precision: Delivers cargo specifically to organs and tumors systemically or with customizable receptor-based targeting.
- Efficiency & Safety: Transfects a wide range of cell types in vitro with low toxicity.
Thank you USNW for allowing us to use this video
How Nano-in Works?
Nano-in™ combines the strengths of PEI and PLGA to address nucleic acid drug delivery challenges.
- Polyethylenimine (PEI): Efficiently condenses nucleic acids for delivery but is highly toxic due to excess positive charges
- Polylactic-co-Glycolic Acid (PLGA): Non-toxic, FDA-approved, but negatively charged, limiting interaction with nucleic acid
- Innovative Synthesis: Nano-in is synthesized by fragmenting PLGA into smaller units that bond with the positive charged portions of the PEI, neutralizing them to reduce toxicity while maintaining its function and delivery efficiency.
- Outcome: A scalable and safer drug delivery platform with enhanced chemical and formulation stability, reduced toxicity, and the ability to overcome biological barriers for efficient nucleic acid delivery for both research and therapeutic development.
The Uniqueness of Nano-in™
Key Differentiators:
Traditional systems like liposomes and viral vectors have limitations such as off-target effects, high costs, and immune responses.
Nano-in™ overcomes these by combining safety, efficiency, and scalability in a single platform.
|
Feature
|
Nano-in
|
Liposomes
|
Viral Vectors
|
|---|---|---|---|
|
Safety
|
Low toxicity, non-immunogenic
|
High immunogenicity, risk of immune responses
|
|
|
Stability
|
Stable at room temperature for 30+ weeks
|
Requires cold-chain logistics
|
Limited stability, requires cryopreservation
|
|
Delivers small RNAs to large plasmids
|
Limited to small or moderate-sized cargo
|
Restricted to specific cargo sizes
|
|
|
Targeting
|
Customizable receptor-mediated targeting
|
Passive or limited targeting
|
Some specificity but risk of off-target effects
|
|
High cost, difficult to scale
|
Learn how Nano-in™ is paving the way for next-generation cancer treatments:
Patents and Intellectual Property Content
Nano-in™ is protected by Speratum Biopharma’s robust intellectual property portfolio:
- US11613609B2 Patent: Covers the innovative use of PLGA-modified PEI nanotechnology (LGA-PEI) for nucleic acid delivery with low cytotoxicity.
- Why It Matters: approach remains exclusive to Speratum, providing a competitive edge in oncology.
